Our senior management team provides a breadth of experience across the pharmaceutical, life sciences and biopharmaceuticals industries throughout the organization — from our executive leadership team, to our hands-on scientists, to members of our finance and product development teams.
President and Chief Executive Officer
Alicia Secor joined Juniper Pharmaceuticals as Chief Executive Officer in August 2016 and serves as a Director of the Company. Ms. Secor brings more than 25 years’ of leadership experience as a life sciences executive, with a track record in leading businesses and advancing products from clinical development through regulatory approval, commercialization, and global expansion across several therapeutic areas.
Ms. Secor joined Juniper from Zafgen, Inc., where she was Chief Commercial Officer and played a key role in advancing the company to a Phase 3 pre-commercialization status. Previously Ms. Secor served 15 years at Genzyme Corporation in diverse leadership roles, most recently as the Global General Manager for the Metabolic Disease Business.
During her tenure at Genzyme, Ms. Secor led fully integrated businesses, successfully launching products and achieving sustained revenue growth. Ms. Secor spearheaded several strategic transactions and built high performance teams, resulting in consistent growth and profitability across multiple Genzyme businesses including biomaterials, surgical devices, and injectable therapeutics.
Prior to Genzyme, Ms. Secor held positions at Alkermes in business development, at Centocor (a Johnson & Johnson Company) in clinical and commercial operations. She began her career at Pfizer as a hospital-based sales representative.
Ms. Secor received an M.B.A. from Northeastern University, and a B.S. in Healthcare Administration from the University of New Hampshire.
Chief Operating Officer
Dr. Nikin Patel co-founded and was the former Chief Executive Officer of Molecular Profiles (now known as Juniper Pharma Services). He joined our board of directors in September 2013 when Molecular Profiles was acquired by Juniper Pharmaceuticals (formerly, Columbia Laboratories).
Dr. Patel has over 15 years’ technical experience centered on pharmaceutical analysis and formulation development. His leadership was recognized externally through the U.K.’s most prestigious industry accolade, the Queen’s Award for Enterprise, won by Molecular Profiles in both 2007 and 2011 in the Innovation category.
Dr. Patel holds a first class honours degree and PhD in Pharmacy from the University of Nottingham, and is a Member of the Royal Pharmaceutical Society (MRPharmS). Dr. Patel is also a co-founder of Locate Therapeutics, a specialist regenerative medicine and device company.
Chief Financial Officer, Treasurer and Secretary
Jeff Young joined Juniper in January 2017, bringing over 20 years of financial leadership in the life sciences sector. He most recently served as Chief Financial Officer and Treasurer of OvaScience, a global fertility company focused on new treatment options for women.
During his two-year tenure at OvaScience, Mr. Young led the company’s fundraising efforts and international tax strategy. He was previously the CFO and Treasurer of Transmedics, a developer of medical devices for the maintenance and transport of organs between donors and recipients. Before that, Mr. Young served as CFO and Treasurer at Lantheus Medical Imaging, where he led and managed multiple debt offerings. He joined Lantheus from Critical Therapeutics, where he was Chief Accounting Officer. Early in his career, he worked in various finance roles at PerkinElmer, Inc., and PriceWaterhouseCoopers LLP.
Mr. Young is a Certified Public Accountant and holds a Bachelor of Science in Business Administration from Georgetown University.
Chief Medical Officer
Dr. Martell brings more than 15 years’ experience in clinical product development, medical affairs and academia to Juniper, including expertise in establishing regulatory strategies for clinical programs and creating submission readiness packages. Before joining Juniper, Dr. Martell was the founder and managing director of BAM Consultants, which provided clinical development and medical affairs consulting services to a broad array of specialty pharmaceutical companies. Prior to that, she oversaw the clinical product development and medical affairs activities at Purdue Pharma and for several business units within Pfizer.
Dr. Martell holds a Bachelor of Science from Cornell University, Master of Arts from Boston University, and a Doctor of Medicine degree from The Chicago Medical School. She completed her internship and residency in Internal Medicine, was a Chief Resident, and a Robert Wood Johnson Clinical Scholar at Yale University School of Medicine. She is board certified in both Internal and Addiction Medicine.
Chief Scientific Officer
Dr. Shen Luk has over 20 years of technical experience in the pharmaceutical and chemical industries. Since joining Juniper Pharma Services, in 2000, Dr. Luk has been integral in developing the company’s scientific breadth and rigor. He leads and consults on a diverse array of analytical, characterization and pharmaceutical development projects. Over the past decade, Dr. Luk has also used his extensive analytical and characterization expertise for pharmaceutical systems to assist and consult in litigation matters surrounding intellectual property. Previously, Dr. Luk spent ten years working in the chemicals industry at Courtalds Corporate Research Laboratories.
Dr. Luk holds a Chemistry degree and doctorate from the University of Manchester’s Institute of Science and Technology.
Senior Vice President, Juniper Pharma Services
Dr. Claire Madden-Smith has served at Juniper Pharma Services for over a decade. She brings over 15 years of CRO business and technical experience, leading our commercial team and pharmaceutical development service. Dr. Madden-Smith instills a consultative approach to the development of new business opportunities.
Dr. Madden-Smith holds a degree in Chemistry and a doctorate in Physical Chemistry from Loughborough University. Previously she has chaired the Marketing Committee of the Controlled Release Society and served on the Materials Science focus group of the Academy of Pharmaceutical Science GB.